ArriVent BioPharma (NASDAQ:AVBP) Stock Price Expected to Rise, Oppenheimer Analyst Says
ArriVent BioPharma (NASDAQ:AVBP – Free Report) had its price objective raised by Oppenheimer from $39.00 to $44.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have an outperform rating on the stock. Other research analysts also recently issued reports about the company. Guggenheim reiterated a “buy” rating and set a $45.00 […]
ArriVent BioPharma (NASDAQ:AVBP – Free Report) had its price objective raised by Oppenheimer from $39.00 to $44.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have an outperform rating on the stock. Other research analysts also recently issued reports about the company. Guggenheim reiterated a “buy” rating and set a $45.00 […]
